Michael Kassardjian, DO
Dermatology · Torrance, CANPI 1740567981
Payments from drug & device makers
Across 133 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$427
- Johnson & Johnson$282
- AbbVie$281
- Galderma Laboratories, L.p.$213
- Almirall LLC$155
- Amgen$154
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,563100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 21 | $427 |
| Johnson & Johnson | 18 | $282 |
| AbbVie | 12 | $281 |
| Galderma Laboratories, L.p. | 13 | $213 |
| Almirall LLC | 7 | $155 |
| Amgen | 5 | $154 |
| Sun Pharmaceutical Industries Inc. | 7 | $147 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $141 |
| Mayne Pharma Commercial LLC | 8 | $120 |
| LEO Pharma Inc. | 5 | $98 |
| Medimetriks Pharmaceuticals, Inc. | 5 | $97 |
| Lilly USA, LLC | 3 | $62 |
| Prugen, Inc. Pharmaceuticals | 4 | $57 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| UCB, Inc. | 2 | $42 |
| Sanofi | 1 | $37 |
| Aclaris Therapeutics, Inc. | 2 | $35 |
| Stimlabs LLC | 1 | $25 |
| Biofrontera Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Glenmark Therapeutics Inc. | 1 | $16 |
| Journey Medical Corporation | 1 | $16 |
| Organon | 1 | $13 |
| VYNE Pharmaceuticals Inc. | 1 | $13 |
| EPI Health, LLC | 1 | $13 |
| Mission Pharmacal Company | 1 | $12 |
How this compares
$2,563 in reported general payments places this provider in the 55th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 94 | $6,967 |
| Ketoconazole | 217 | $3,135 |
| Clobetasol Propionate | 55 | $2,314 |
| Fluocinonide | 53 | $1,520 |
| Tacrolimus | 12 | $1,352 |
| Metronidazole | 22 | $1,325 |
| Ciclopirox | 38 | $1,324 |
| ValacyclovirValacyclovir Hcl | 49 | $1,035 |
| Triamcinolone Acetonide | 158 | $966 |
| Betamethasone Dipropionate | 28 | $894 |
| Clindamycin Phosphate | 25 | $814 |
| Desonide | 41 | $804 |
| Betamethasone Valerate | 33 | $782 |
| Mupirocin | 81 | $469 |
| Imiquimod | 16 | $458 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Torrance
- Vivian LaquerIrvine$20.9M
- Howard SofenLos Angeles$16.1M
- Raja SivamaniSacramento$11.8M
- Jennifer SoungSanta Ana$10.3M
- Stacy SmithEncinitas$7.9M
- Paul YamauchiSanta Monica$7.8M
- Navid EzraThousand Oaks$7.8M
- Paul WallaceBeverly Hills$7.1M
- April ArmstrongLos Angeles$6.2M
- David RayhanHuntington Beach$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.